R&D PIPELINE THERAPY AREAS

R&D Pipeline Therapy Areas

The agents and uses mentioned below are investigational and have not been approved by the US Food and Drug Administration (FDA) for the uses under investigation. No conclusions regarding safety and efficacy should be drawn for such agents and uses.
Sanofi is investigating multiple sources of damage in the brain that contribute to progression of multiple sclerosis (MS). Sanofi is also expanding the focus of its research to other neurological diseases, such as chronic inflammatory demyelinating polyneuropathy (CIDP).

Latest News from Sanofi

Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis

Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS

Educational Resources

General

Pre-approval Information Exchange: Overview of the Sanofi Specialty Care Pipeline
A presentation providing a brief general overview of Sanofi’s specialty care R&D pipeline, including investigational agents and proposed mechanistic targets in MS, and CIDP. All information is updated quarterly.

Multiple Sclerosis

Tolebrutinib Phase 3 Trials Overview Brochure
Description of the Tolebrutinib Phase3 Clinical trials

GEMINI and HERCULES Phase 3 Baseline Demographics Understanding Tolebrutinib
Description of the baseline demographics for the Tole Phase 3 studies